Presentations featured in the Symposium agenda include:

Welcome Remarks
Vincenzo Valentini, M.D., Gemelli ART, Rome, Italy

MR-Guided RT Primer (The MRIdian Advantage)
Martin Fuss, M.D., Chief Medical Officer, ViewRay
Considerations and Challenges of MR-Guided RT (Physics)
Kristian Boye Ph.D., Rigshospitalet, Copenhagen, Denmark
On-Table Adaptive MR Image-Guided RT: Considerations for QA
Lorenzo Placidi, medical physicist, Gemelli ART, Rome, Italy
MR-Guided Renal Cell Cancer SBRT
Anna Bruynzeel, M.D., Ph.D., Amsterdam UMC, Netherlands
Clinical Studies/Clinical Research Overview
Paul Strong, Ph.D., Senior Director, Medical Affairs, ViewRay
Access to Innovative Radiotherapy: How to Make it Happen from an Economic Perspective
Yolande Lievens, M.D., Ph.D., Ghent University Hospital, Ghent, Belgium, ESTRO-HERO
On-Table Adaptive MR-Guided SBRT: Clinical Experience at Gemelli
Luca Boldrini, M.D., Gemelli ART, Rome, Italy
Decision Making Process Towards MRIdian
Pascal Fenoglietto, M.D., Institut du Cancer Montpellier (ICM)
MR-Guided SBRT, Results Phase 2: Prostate SMART study (Amsterdam UMC Experience)
Frank Lagerwaard, M.D., Amsterdam UMC, Netherlands
Closing Remarks
Piercarlo Gentile, M.D., San Pietro Fatebenefratelli UPMC, Rome, Italy
Please note, this event is intended for medical professionals only, including radiation oncologists, medical physicists, radiation therapists and hospital administrators.


About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.


SOURCE ViewRay, Inc.

Back to HCB News

MRI Homepage